FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152718575> ?p ?o ?g. }

• W3152718575 endingPage "102830" @default.
• W3152718575 startingPage "102830" @default.
• W3152718575 abstract "Interstitial lung disease (ILD) is a serious complication that represents the second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA-ILD remains controversial. The absence of randomized clinical trials and specific ACR or EULAR therapeutic guidelines makes it difficult to establish solid therapeutic recommendations on this issue. In this scenario, real-world data is especially valuable.To review the literature evidence on the efficacy and safety of abatacept (ABA) for the treatment of rheumatoid arthritis (RA) with associated interstitial lung disease (ILD), given its clinical relevance and the lack of consensus on its therapeutic management.PUBMED and EMBASE were searched from the date of approval of ABA to the end of 2020 using a combination of RA, ILD and ABA terms following PRISMA guidelines. Identified studies were evaluated by two independent investigators.Nine original studies (1 case series and 8 observational studies) were selected for inclusion in the systematic review. No randomized trial or meta-analysis were identified. The mean age of patients ranged from 61.2 to 75 years and the mean RA duration varied from 7.4 to 18 years. Subcutaneous ABA (74.5%-91%) predominated in combination with conventional synthetic DMARDs (csDMARDs) (58%-75%), and it was used as first-line biologic agent in 22.8%-64.9% of the patients. The mean course of ILD ranged from 1 to 6.7 years, being usual and nonspecific interstitial pneumonia the most frequent patterns. Improvement or stabilization of ILD imaging (76.6%-92.7%) and FVC or DLCO (>85%) was described after a mean follow-up of 17.4-47.8 months, regardless of the pattern of lung involvement, being more remarkable in patients with shorter evolution of ILD. ABA led to significantly lower ILD worsening rates than TNF inhibitors (TNFi) and was associated with a 90% reduction in the relative risk of deterioration of ILD at 24 months of follow-up compared to TNFi and csDMARDs. Combination with methotrexate may have a corticoid-sparing effect. No unexpected adverse events were identified.Current evidence suggests that ABA may be a plausible alternative to treat RA patients with ILD. It would be highly desirable to develop prospective randomized controlled studies to confirm these findings." @default.
• W3152718575 created "2021-04-26" @default.
• W3152718575 creator A5012858626 @default.
• W3152718575 creator A5014762324 @default.
• W3152718575 creator A5016922988 @default.
• W3152718575 creator A5020380174 @default.
• W3152718575 creator A5031531166 @default.
• W3152718575 creator A5076782477 @default.
• W3152718575 creator A5077379208 @default.
• W3152718575 date "2021-06-01" @default.
• W3152718575 modified "2023-10-17" @default.
• W3152718575 title "Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review" @default.
• W3152718575 cites W1737953065 @default.
• W3152718575 cites W1875585421 @default.
• W3152718575 cites W1977252928 @default.
• W3152718575 cites W1998500500 @default.
• W3152718575 cites W2016323579 @default.
• W3152718575 cites W2016454440 @default.
• W3152718575 cites W2021354645 @default.
• W3152718575 cites W2022441502 @default.
• W3152718575 cites W2030324505 @default.
• W3152718575 cites W2062811499 @default.
• W3152718575 cites W2069826111 @default.
• W3152718575 cites W2077659453 @default.
• W3152718575 cites W2096455579 @default.
• W3152718575 cites W2101743615 @default.
• W3152718575 cites W2105367456 @default.
• W3152718575 cites W2113377455 @default.
• W3152718575 cites W2113609304 @default.
• W3152718575 cites W2116120939 @default.
• W3152718575 cites W2118561596 @default.
• W3152718575 cites W2124670599 @default.
• W3152718575 cites W2128952811 @default.
• W3152718575 cites W2130829606 @default.
• W3152718575 cites W2133789608 @default.
• W3152718575 cites W2145984110 @default.
• W3152718575 cites W2149661971 @default.
• W3152718575 cites W2152015928 @default.
• W3152718575 cites W2152348310 @default.
• W3152718575 cites W2152350812 @default.
• W3152718575 cites W2156098321 @default.
• W3152718575 cites W2160885249 @default.
• W3152718575 cites W2164738490 @default.
• W3152718575 cites W2187573191 @default.
• W3152718575 cites W2197347269 @default.
• W3152718575 cites W2333249749 @default.
• W3152718575 cites W2338022605 @default.
• W3152718575 cites W2339383202 @default.
• W3152718575 cites W2343443246 @default.
• W3152718575 cites W2523806075 @default.
• W3152718575 cites W2608504023 @default.
• W3152718575 cites W2612997596 @default.
• W3152718575 cites W2624044307 @default.
• W3152718575 cites W2624537152 @default.
• W3152718575 cites W2626574050 @default.
• W3152718575 cites W2782148001 @default.
• W3152718575 cites W2806460375 @default.
• W3152718575 cites W2888212400 @default.
• W3152718575 cites W2888804839 @default.
• W3152718575 cites W2901315852 @default.
• W3152718575 cites W2905072001 @default.
• W3152718575 cites W2906253210 @default.
• W3152718575 cites W2916179527 @default.
• W3152718575 cites W2916944786 @default.
• W3152718575 cites W2919355697 @default.
• W3152718575 cites W2935343188 @default.
• W3152718575 cites W2936666488 @default.
• W3152718575 cites W2944128731 @default.
• W3152718575 cites W2946185509 @default.
• W3152718575 cites W2946919477 @default.
• W3152718575 cites W2953602195 @default.
• W3152718575 cites W2956306002 @default.
• W3152718575 cites W2970695757 @default.
• W3152718575 cites W2981111930 @default.
• W3152718575 cites W2982587776 @default.
• W3152718575 cites W2987008883 @default.
• W3152718575 cites W2991792334 @default.
• W3152718575 cites W2995255465 @default.
• W3152718575 cites W2996213468 @default.
• W3152718575 cites W2999979644 @default.
• W3152718575 cites W3003676627 @default.
• W3152718575 cites W3025891184 @default.
• W3152718575 cites W3036280964 @default.
• W3152718575 cites W3081522071 @default.
• W3152718575 cites W3088349851 @default.
• W3152718575 cites W3093381665 @default.
• W3152718575 cites W3111707249 @default.
• W3152718575 cites W4240531797 @default.
• W3152718575 cites W4252060375 @default.
• W3152718575 doi "https://doi.org/10.1016/j.autrev.2021.102830" @default.
• W3152718575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33887489" @default.
• W3152718575 hasPublicationYear "2021" @default.
• W3152718575 type Work @default.
• W3152718575 sameAs 3152718575 @default.
• W3152718575 citedByCount "31" @default.
• W3152718575 countsByYear W31527185752021 @default.
• W3152718575 countsByYear W31527185752022 @default.
• W3152718575 countsByYear W31527185752023 @default.

• next